1 / 10

Early Experience With Anterior Chamber Phakic IOL

Early Experience With Anterior Chamber Phakic IOL. Ahmed El- Massry M.D. Professor of Ophthalmology Alexandria University Egypt. The author has no financial interest in the subject matter of this e-poster. US Status: Investigational device limited by Federal Law to investigational use only.

heffner
Télécharger la présentation

Early Experience With Anterior Chamber Phakic IOL

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Early Experience With Anterior Chamber Phakic IOL Ahmed El-Massry M.D. Professor of Ophthalmology Alexandria University Egypt The author has no financial interest in the subject matter of this e-poster. US Status: Investigational device limited by Federal Law to investigational use only

  2. ICARE(Corneal) PMMA (IOL Tech) ZSAL4(Morcher) NuVita MA20(B&L) NewLife (IOL Tech) Kelman Duet (Tekia) Vivarte (Ciba) Refractive Options – Anterior Chamber(Angle Supported )

  3. Design Challenges • Achieve low compression force • Gentle on delicate ocular tissues • Avoid pupil ovalization • Decrease inflammation • Maintain stabilitydespite low compression force • Ensurelow vault response as a function of compression • Critical for safe placement within anterior chamber • Facilitate reliable small incision surgery • Low inflammation and surgical induced astigmatism

  4. Anterior Chamber Ocular Coherence Tomography Optic 2/3 2/3 Bridge Footplate 1/3 1/3 Iris Crystalline Lens Ideal Lens Position in vivo(no iridectomy/iridotomy required) *ZEISS is a registered trademarks of Carl Zeiss AG.

  5. purpose • To evaluate the efficacy, stability , endothelial cell count, visual outcome , higher order aberration changes , IOP and lens position of one type of Phakic IOLs (Cachet produced by Alcon Laboratories) on six month period of follow up.

  6. Methods • A prospective non randomized single center study was done on: - Twenty eyes of high myopes. -That are eligible for anterior chamber phakic IOLs. -Ranged from -10.00 Diopters to -16.50 Diopters. -Anterior chamber depth is not less than 3.5mm. -Endothelial cell count was not less than 2500 cells / mm2 -Age ranged from 26 to 33 years of age . In one eye opposite clear corneal incision was done to correct 1.0 Diopter of astigmatism.

  7. Methods • All cases were operated under general anesthesia in Alex Eye Center in Alexandria, Egypt. • Phakic IOL (Cachet type of Alcon Laboratories) had been inserted for all the 20 eyes. • 12 eyes for females and 8 were males • No intraoperative complication had been reported.

  8. Results • Early results showed Uncorrected visual acuity of 0.8 to 1.0 on Snellen's chart in all eyes day 7 after surgery . • One eye had a spike of increased IOP six hours after surgery and had been controlled by oral Carbonic anhydrase inhibitor drug. • Six months follow up results of endothelial cell count , stability of the IOL, IOP showed non significant changes than preoperative data.

  9. Conclusions • Early results show good visual outcome of the new phakic Cachet IOLs . • Longer period of follow up is needed to evaluate stability and endothelial cell count for this new lens .

  10. Thank you

More Related